Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have significantly advanced the management of type 2 diabetes mellitus (T2DM) and obesity, with much of the literature focusing on the synthesis of associated risks [1,2]—including gastrointestinal events, psychiatric symptoms, and ocular complications—that warrant careful consideration in clinical practice. However, an equally important dimension of GLP-1 RA therapy is patient adherence, which directly influences both safety and therapeutic effectiveness. Several pharmaceutical companies are advancing oral GLP-1 RAs to improve adherence and patient acceptability in the treatment of T2DM and obesity. Semaglutide (Rybelsus, Novo Nordisk, Bagsvaerd, Denmark) remains the only U.S. Food and Drug Administration-approved oral GLP-1 RA to date [3]. Investigational oral GLP-1 RAs under development include orforglipron (Eli Lilly, Indianapolis, IN, USA; phase 3 [4]), GSBR-1290 (Structure Therapeutics, South San Francisco, CA, USA; phase 2), and HS‑10535 (Hansoh Pharma [Lianyungang, China], licensed to Merck [Rahway, NJ, USA] in 2023 [5]), while earlier-stage candidates such as the dual GLP-1/glucose-dependent insulinotropic polypeptide receptor agonist HS-20094—licensed by Regeneron from Hansoh Pharma in June 2025 and currently in phase 3 trials—underscore the growing industry-wide pursuit of orally delivered incretin-based therapies.

Research comparing real-world adherence to oral GLP-1 RAs versus injectable GLP-1 RAs remains scarce. Our recent analysis of over 78,000 commercially insured adults in the United States from 2010 to 2022 offers additional context to the discussion. We conducted a retrospective analysis of IQVIA PharMetrics Plus for Academics (IQVIA, Durham, NC, USA), a 25% random sample of a national longitudinal health plan database that includes fully adjudicated medical and pharmacy claims for commercially insured individuals in the United States. We identified adults aged 18 to 65 who initiated a GLP-1 RA between 2010 and 2022 and had more than 6 months of follow-up data. Given that newer agents like oral semaglutide were introduced later in the study period, we restricted our analysis to each agent’s index prescription. The index prescription was defined as the first observed GLP-1 RA prescription following a minimum 90-day period without any prior GLP-1 RA use [6]. Baseline comorbidities, including T2DM and obesity, were identified via International Classification of Diseases, 10th Revision (ICD-10) codes from the index year and preceding years. Adherence was assessed using the proportion of days covered (PDC), with PDC ≥80% [7] indicating high adherence, calculated over both 6-month [6] and 12-month [8] periods. We monitored prescription fills beyond the 6- or 12-month adherence window, classifying gaps >90 days as discontinuation and any reinitiation after such a gap as a new treatment episode with a new index date. This approach enabled a more balanced comparison of adherence across agents within a contemporaneous clinical context. All analyses were conducted using Python version 3.11.8 (Python Software Foundation, Wilmington, DE, USA). This study was deemed exempt from Institutional Review Board approval due to unidentifiable data.

In our analytic sample of 78,297 patients prescribed GLP-1 RAs with >6 months follow-up, the median age was 53 years, and 55.3% were female. More than half of the patients (54.7%) had both T2DM and obesity concurrently, while 40.4% had T2DM only and 4.9% had obesity only. Most patients (98.9%) were prescribed injectable GLP-1 RAs; liraglutide accounted for the largest share of prescriptions (60.3%), followed by dulaglutide (25.0%) and injectable semaglutide (8.6%). At 6 months, mean PDC ranged between 58% to 69.5%, reflecting moderate overall adherence (Table 1). Less than half (range 28% to 49.7%) of the patients achieved high adherence (PDC ≥80%). At 12-month follow-up, mean PDC improved across all agents (69.8% to 82.4%). The proportion of patients achieving high adherence (PDC ≥80%) was highest for oral semaglutide (65.1%), followed by dulaglutide (59.1%), and lowest for liraglutide/insulin degludec (34.9%) and injectable semaglutide (38.8%).

In our nationally representative cohort of commercially insured adults prescribed GLP-1 RAs between 2010 and 2022, adherence was moderate and varied across agents over a 6-month follow-up. Liraglutide was the most commonly prescribed agent, but less than half of patients (44.5%) reached high adherence (>80% PDC) by 12-month follow-up. Oral semaglutide showed the highest adherence (65.1%) but was much less commonly prescribed. Oral semaglutide demonstrated higher adherence than injectable semaglutide at both 6 and 12 months. While this may suggest greater convenience [9] of oral agents, the adherence advantage could also reflect unmeasured confounding by indication, health literacy, socioeconomic status, insurance coverage, and adverse event profiles. Pharmaceutical companies are increasingly developing oral GLP-1 RA formulations to align with patient preferences and enhance treatment adherence. Given that higher adherence to GLP-1 RAs is generally associated with improved glycemic control and weight reduction [10,11], our finding of enhanced adherence with the oral formulation may have important implications for industry stakeholders.

Several limitations warrant consideration. First, administrative claims data lack clinical details (e.g., glycosylated hemoglobin, blood pressure, renal function) and reasons for discontinuation. Second, oral semaglutide users represented only 1.1% of the cohort (871 patients), which limited the statistical power to detect adherence differences compared to injectable formulations. Third, the study was restricted to commercially insured adults aged 18 to 65 in the United States, limiting generalizability to commercially insured and older adults. Interestingly, adherence rates at 12 months exceeded those at 6 months across several agents. It may reflect that only persistent users remain in the 12-month analytic sample. Individuals who continue therapy beyond 6 months likely represent a more adherent subpopulation. This phenomenon, commonly referred to as the ‘healthy adherer effect [12],’ was a common confounder in observational studies. Last, fixed-dose combinations of GLP-1 RAs with basal insulin (e.g., degludec and glargine) may have more flexible, patient-adjusted dosing schedules, which can reduce fill frequency despite good adherence. As such, our PDC estimates may underestimate adherence for these agents.

Our study demonstrates that real-world adherence to GLP-1 RAs varies substantially across agents, with adherence to oral semaglutide exceeding that observed for most injectable formulations. Adherence patterns in real-world settings are shaped by a complex interplay of measurable factors [13]—such as patient demographics, comorbidities, medication burden, and documented adverse events—and unmeasured determinants, including health literacy, treatment beliefs, and patient preferences. These findings suggest that formulation characteristics—particularly the route of administration—may meaningfully influence real-world persistence and adherence, which in turn could affect downstream clinical outcomes.

NOTES

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

ACKNOWLEDGMENTS

Any opinions, findings, conclusions, or recommendations expressed in this publication are those of the authors and do not necessarily reflect the views of the IQVIA Inc.

REFERENCES

• 1. Kim JA, Yoo HJ. Exploring the side effects of GLP-1 receptor agonist: to ensure its optimal positioning. Diabetes Metab J 2025;49:525-41.ArticlePubMedPMCPDF
• 2. Kim M, Kim SC, Kim J, Kim BH. Use of glucagon-like peptide-1 receptor agonists does not increase the risk of cancer in patients with type 2 diabetes mellitus. Diabetes Metab J 2025;49:49-59.ArticlePubMedPDF
• 3. Anderson SL, Beutel TR, Trujillo JM. Oral semaglutide in type 2 diabetes. J Diabetes Complications 2020;34:107520.ArticlePubMed
• 4. Eli Lilly and Company. Lilly’s oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful phase 3 trial. Available from: https://www.prnewswire.com/news-releases/lillys-oral-glp-1-orforglipron-demonstratedstatistically-significant-efficacy-results-and-a-safety-profileconsistent-with-injectable-glp-1-medicines-in-successfulphase-3-trial-302430985.html (cited 2025 Sep 18).
• 5. Merck & Co. I. Merck enters into exclusive global license agreement with Hansoh Pharma for investigational oral GLP-1 receptor agonist. Available from: https://www.merck.com/news/merck-enters-into-exclusive-global-license-agreement-withhansoh-pharma-for-investigational-oral-glp-1-receptor-agonist/ (cited 2025 Sep 18).
• 6. Durden E, Liang M, Fowler R, Panton UH, Mocevic E. The effect of early response to GLP-1 RA therapy on long-term adherence and persistence among type 2 diabetes patients in the United States. J Manag Care Spec Pharm 2019;25:669-80.ArticlePubMed
• 7. Weeda ER, Muraoka AK, Brock MD, Cannon JM. Medication adherence to injectable glucagon-like peptide-1 (GLP-1) receptor agonists dosed once weekly vs once daily in patients with type 2 diabetes: a meta-analysis. Int J Clin Pract 2021;75:e14060.ArticlePubMedPDF
• 8. Qiao Q, Ouwens MJ, Grandy S, Johnsson K, Kostev K. Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany. Diabetes Metab Syndr Obes 2016;9:201-5.PubMedPMC
• 9. Andersen A, Knop FK, Vilsboll T. A pharmacological and clinical overview of oral semaglutide for the treatment of type 2 diabetes. Drugs 2021;81:1003-30.ArticlePubMedPMCPDF
• 10. Palanca A, Ampudia-Blasco FJ, Calderon JM, Sauri I, Martinez-Hervas S, Trillo JL, et al. Real-world evaluation of GLP-1 receptor agonist therapy persistence, adherence and therapeutic inertia among obese adults with type 2 diabetes. Diabetes Ther 2023;14:723-36.ArticlePubMedPMCPDF
• 11. Carls GS, Tan R, Zhu JY, Tuttle E, Yee J, Edelman SV, et al. Real-world weight change among patients treated with glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor and sulfonylureas for type 2 diabetes and the influence of medication adherence. Obes Sci Pract 2017;3:342-51.ArticlePubMedPMCPDF
• 12. Andersohn F, Willich SN. The healthy adherer effect. Arch Intern Med 2009;169:1635-6.ArticlePubMed
• 13. Gow K, Rashidi A, Whithead L. Factors influencing medication adherence among adults living with diabetes and comorbidities: a qualitative systematic review. Curr Diab Rep 2024;24:19-25.ArticlePubMedPDF

Figure & Data

References

Citations

Citations to this article as recorded by  

About this article

Wang SY, Stofer R, Wang H, Brent GA, Shi L, Cai Y, Roosan M, Moin T. Bridging Efficacy and Adherence in Glucagon-Like Peptide-1 Receptor Agonist Therapy: The Emerging Role of Oral Agents. Diabetes Metab J. 2025;49(6):1331-1333.

DOI: https://doi.org/10.4093/dmj.2025.0666.

Download citation ↓